ACCENTIA BIOPHARMACEUTICALS, INC.
Exhibit 10.4
ACCENTIA BIOPHARMACEUTICALS, INC.
| September 30, 2010 (Unaudited) | ||||
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | $ | 556,392 | ||
| Accounts receivable: | ||||
| Trade, net of allowance for doubtful accounts of $10,031 at June 30, 2010 and September 30, 2009 | 1,287,366 | |||
| Inventories | 417,087 | |||
| Unbilled receivables | 151,303 | |||
| Prepaid expenses and other current assets | 243,998 | |||
| Total current assets | 2,656,146 | |||
| Goodwill | 893,000 | |||
| Intangible assets | 1,083,962 | |||
| Furniture, equipment and leasehold improvements, net | 154,434 | |||
| Deferred finance costs, less current portion | 16,077 | |||
| Other assets | 216,791 | |||
| $ | 5,020,410 | |||
| LIABILITIES | ||||
| Liabilities not subject to compromise: | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 1,125,877 | ||
| Accrued expenses | 1,791,856 | |||
| Unearned revenues | 263,778 | |||
| Notes payable, related parties | 2,041,005 | |||
| Customer deposits | 134,613 | |||
| Derivative liability | 1,844,200 | |||
| Total current liabilities | 7,201,329 | |||
| Liabilities subject to compromise | 142,886,695 | |||
| Total liabilities | 150,058,024 | |||
| Commitments and contingencies | — | |||
| Series A convertible redeemable preferred stock, $1.00 par value; 8,950 shares authorized; 7,529 shares issued and outstanding at June 30, 2010 and September 30, 2009 | 7,528,640 | |||
